Overview

Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)

Status:
Completed
Trial end date:
2001-11-01
Target enrollment:
Participant gender:
Summary
Patients were treated with either montelukast 4 mg oral granules or usual care. Patients who completed Protocol MK0476-176-01 (NCT00943683) had the option to enroll in this study. Additionally, patients with asthma who were 6 to 11 months of age and who had not participated in Protocol MK0476-176-01, could also enroll.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Montelukast